Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459216 | 0.88 | SMN1; SMN2 (0.44) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL1008401 | 0.88 | SMN1; SMN2 (0.44) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL1007316 | 0.88 | SMN1; SMN2 (0.44) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL1870478 | 0.83 | HSD17B10 (0.48) | KDM4ESMN1; SMN2TSHRPLGPLAT | |
| SCHEMBL12437051 | 0.82 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL5472061 | 0.80 | KDM4E (0.56) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL21675522 | 0.79 | SMN1; SMN2 (0.42) | KDM4ESMN1; SMN2TSHRPLGPLAT | |
| SCHEMBL1008455 | 0.78 | KDM4E (0.59) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL1010044 | 0.78 | KDM4E (0.54) | KDM4ESMN1; SMN2TSHRPOLBPKM | |
| SCHEMBL1007625 | 0.78 | KDM4E (0.54) | KDM4ESMN1; SMN2TSHRPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | claimed |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-02-18 | — | — | US | claimed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | claimed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-1797062-B1 | ALKYNYL BASED DERVATIVES OF BENZOPHENONE AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-7300948-B2 | Alkynyl compounds as non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | KRAS, NRAS, HRAS | KDM4E 2955/4885SMN1; SMN2 4044/4885TSHR 3389/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | KDM4E 2955/4885SMN1; SMN2 4044/4885TSHR 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.